Navigation Links
Options increase for CML patients failed by existing drugs
Date:12/21/2012

HOUSTON The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved the drug ponatinib (Iclusig), which is effective in a significant number of patients with either disease.

Patients with both leukemias have enjoyed strong responses to imatinib (Gleevec) and second-generation drugs nilotinib (Tasigna) and dasatinib (Sprycel). All work by inhibiting proteins called tyrosine kinases on leukemia cells, in particular the aberrant BCR-ABL protein that causes these diseases.

However, 30-40 percent of CML patients resist imatinib. Nilotinib and dasatinib work for about 40-50 percent of those patients.

"Ponatinib's availability will drastically improve the outcome of most patients with CML and PH+ALL who are resistant or intolerant to prior tyrosine kinase inhibitor therapy," said Jorge Cortes, M.D., professor and deputy chair, in The University of Texas MD Anderson Cancer Center Department of Leukemia.

"Clinical responses to Iclusig have been observed in patients regardless of their mutation status or disease stage. It's a valuable new treatment option for leukemia patients," Cortes said.

New drugs fill gaps in treatment

Ponatinib is the third drug approved by the FDA for CML and Ph+ALL during the past four months, providing oncologists with a wealth of options. Cortes led all of the clinical trials for the three drugs. The other two are bosutinib (Bosulif) and omacetaxine (Synribo). Cortes and other Leukemia Department faculty also led many of the clinical trials for the three previously approved CML therapies.

"It's important to have as many therapies against cancer as we can, because rarely does one drug or combination succeed for all patients," Cortes said. "These new drugs cover different gaps in treatment, so they can serve our patients in different way
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Version 2.0 of Award-Winning Proloquo2Go App for iPhone, iPad & iPod touch Speeds Up Communication, Adds New Voices and Customization Options
2. Mesothelioma Victims Center Now Urges US Navy Veterans Or Individuals With Mesothelioma To Call Them For The Names Of The Best Mesothelioma Attorneys & Treatment Options
3. Menu labeling requirements lead to healthier options at chain restaurants
4. Options Increasing for Coping With Kids Food Allergies
5. Existing drugs offer new treatment options for high-risk childhood leukemia subtype
6. Many options, good outcomes, for early-stage follicular lymphoma
7. Little evidence supports autism treatment options in adolescents
8. New options for ease and accuracy in extraction of rare cells or separating blood
9. Policy considerations pose options for leaders to reduce costly disparities in diabetes
10. Fast food menu options double; calorie counts remain high
11. Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... Saving Benefit Faces Eventual Elimination Without Relief , ... of President Obama,s pledge not to raise taxes on the ... outside of the normal legislative process -- adopting provisions approved ... the use of flexible spending accounts (FSAs) in order to ...
... from a new virtual reality training programme created at ... have been working with researchers in the School of ... scenarios that test expert players, perceptual skills. Lead ... Senior Lecturer in Visual Perception who has previously collaborated ...
... to educate, inform, and empower the people of Chicago, ... its 25-minute live call-in show, "Community Health," on ... at 6:00 PM on Channel 21. , ... Health Clinics with Erin Buckley, FNP-C, Certified Family Nurse ...
... Oct. 14 Peter Sheldon, Vice President of Operations ... commercial cleaning businesses, will be a featured speaker at ... to be held on October 14-15 at The Fairmont ... is "Be the Best in Your Business with Best ...
... 15, 2009 marks the 35th anniversary of the founding of ... McDonald Houses in 52 countries and regions throughout the world, ... the Philadelphia House,s two locations (on Chestnut Street, and at ... McDonald House of Southern New Jersey, the world,s 51st House, ...
... ... a few years ago, today it seems "Natural" is the new buzz word in retail, ... Buster was recently featured on an episode of The Dr. Oz Show in a segment ... ...
Cached Medicine News:Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:Increased success a 'virtual' certainty for rugby players 2Health News:Retail Health Clinics - The Real Story 2Health News:Coverall Executive Peter Sheldon To Be Featured Speaker at PRSM Mid-Year Conference 2Health News:Philadelphia-Born Ronald McDonald House(R) Program Celebrates 35 Years 2Health News:Philadelphia-Born Ronald McDonald House(R) Program Celebrates 35 Years 3Health News:Sinus Buster Paves the Way for Natural OTC Products and Mainstream Success 2
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today ... HYLENEX manufacturing and has identified a corrective action plan ... Halozyme and Baxter are finalizing the materials for a ... seek concurrence with the reintroduction strategy. During several meetings ...
... LONDON, Aug. 31 Following a recent analysis ... Sullivan presented Lodox Systems (Pty) Ltd (Lodox) with ... Leadership Award".  Statscan, Lodox,s digital x-ray product, stunned ... diagnostic, whole-body x-ray pictures in just 13 seconds. ...
Cached Medicine Technology:Halozyme Provides HYLENEX® Product Reintroduction Update 2Halozyme Provides HYLENEX® Product Reintroduction Update 3Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 2Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 3Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 4
Lambotte periosteal elevators....
Modified Freer periosteal elevator, #163, slight curve, 21 cm....
Williger periosteal elevator, 6 1/4", sharp, 5 mm wide....
Alley periosteal elevator, extra long, 21 cm, 8-1/4"....
Medicine Products: